IRIS UniCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.501
NA - Nord America 4.414
EU - Europa 3.059
SA - Sud America 1.271
AF - Africa 243
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.513
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.213
SG - Singapore 2.872
BR - Brasile 1.042
CN - Cina 928
IT - Italia 602
VN - Vietnam 509
SE - Svezia 492
FR - Francia 392
DE - Germania 383
IE - Irlanda 323
ID - Indonesia 236
FI - Finlandia 177
GB - Regno Unito 175
IN - India 166
HK - Hong Kong 160
JP - Giappone 150
RU - Federazione Russa 150
CI - Costa d'Avorio 116
CA - Canada 97
AR - Argentina 85
BD - Bangladesh 80
IQ - Iraq 66
ES - Italia 58
KR - Corea 58
MX - Messico 58
NL - Olanda 56
PL - Polonia 52
TR - Turchia 40
EC - Ecuador 38
ZA - Sudafrica 36
AT - Austria 35
PK - Pakistan 35
SA - Arabia Saudita 34
MA - Marocco 24
UA - Ucraina 23
CO - Colombia 22
CZ - Repubblica Ceca 22
VE - Venezuela 22
AU - Australia 21
KE - Kenya 21
RO - Romania 20
CL - Cile 18
JO - Giordania 17
CH - Svizzera 15
AE - Emirati Arabi Uniti 14
TH - Thailandia 14
PY - Paraguay 13
UZ - Uzbekistan 13
PE - Perù 12
TN - Tunisia 12
IR - Iran 11
LT - Lituania 11
EG - Egitto 10
GR - Grecia 10
BE - Belgio 9
BO - Bolivia 9
CR - Costa Rica 9
IL - Israele 9
MY - Malesia 9
PH - Filippine 9
PT - Portogallo 9
KZ - Kazakistan 8
NP - Nepal 8
HU - Ungheria 7
JM - Giamaica 7
LB - Libano 7
UY - Uruguay 7
AL - Albania 6
BG - Bulgaria 6
CY - Cipro 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HN - Honduras 6
TT - Trinidad e Tobago 6
TW - Taiwan 6
HR - Croazia 5
KW - Kuwait 5
MD - Moldavia 5
PA - Panama 5
RS - Serbia 5
AZ - Azerbaigian 4
DZ - Algeria 4
AO - Angola 3
BH - Bahrain 3
GE - Georgia 3
MM - Myanmar 3
NG - Nigeria 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BB - Barbados 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
GT - Guatemala 2
GY - Guiana 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
ME - Montenegro 2
Totale 14.491
Salva come PNG Salva come JPEG
Città #
Singapore 1.404
Ashburn 732
San Jose 662
Chandler 425
Dublin 316
Beijing 245
Jakarta 214
Lauterbourg 190
Ho Chi Minh City 175
Hong Kong 150
New York 150
Hefei 149
Milan 143
Tokyo 131
Frankfurt am Main 127
Helsinki 123
Hanoi 122
Abidjan 115
Bremen 115
Rome 115
Moscow 105
Los Angeles 101
Princeton 99
São Paulo 90
Boston 88
Dallas 70
Council Bluffs 68
The Dalles 63
Paris 57
Chicago 55
Santa Clara 52
Munich 50
Seoul 50
Kent 46
Wilmington 41
London 38
Nuremberg 36
Warsaw 34
Washington 34
Montreal 31
Rio de Janeiro 31
Atlanta 30
Pune 30
San Mateo 30
Brasília 29
Amsterdam 28
Lappeenranta 28
Brooklyn 27
Haiphong 26
Seattle 25
Turku 25
St Louis 24
Stockholm 24
Belo Horizonte 23
Da Nang 23
Mexico City 23
Boardman 22
Toronto 22
Curitiba 21
Hyderabad 21
Dhaka 20
Shanghai 20
Vienna 20
Chennai 19
Denver 19
Johannesburg 19
Orem 19
Baghdad 18
Brno 18
Nairobi 18
Houston 17
Amman 16
Hangzhou 16
North Bergen 16
Manchester 15
Buffalo 14
Guarulhos 14
Porto Alegre 14
Redwood City 14
Roubaix 14
San Francisco 14
Ankara 13
Dearborn 13
Guayaquil 13
Jeddah 13
Phoenix 13
Riyadh 13
Düsseldorf 12
Tashkent 12
Guangzhou 11
Mumbai 11
Poplar 11
Salvador 11
Santiago 11
Barcelona 10
Fairfield 10
Madrid 10
New Delhi 10
Ottawa 10
Quito 10
Totale 8.094
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 365
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 220
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 163
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 134
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 127
Drug survival of biologics and non-biologics in patients affected by palmoplantar psoriasis: a “real-world”, mono-center experience 123
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 123
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 122
Assessment of alopecia areata universalis successfully treated with upadacitinib 120
Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients 116
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 114
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 113
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 112
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 112
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 112
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 110
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 110
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 109
Biological agents targeting interleukin-13 for atopic dermatitis 109
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 108
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 108
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 107
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 106
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 106
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 105
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 105
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 105
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 105
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 103
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 103
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 102
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 100
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 98
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 98
Overview of Atopic Dermatitis in Different Ethnic Groups 98
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 96
Topical treatment of severe xerosis: Results of an observational study 96
Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab 95
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 95
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 95
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 95
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 94
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 94
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 94
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 93
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 93
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 93
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 93
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment 92
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 92
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 91
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 91
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 91
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 91
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 89
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 89
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 89
Evaluation of the Impact of Night Shift Work on Disease Severity in Psoriatic Patients: A Case-Control Study with Clinical, Hormonal, and Immunological Evaluation 87
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 86
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study 85
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 85
European consensus statement on phenotypes of pustular psoriasis 85
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 84
Drug survival of methotrexate and predictor factors for discontinuation in psoriasis 83
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 83
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 83
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 82
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 82
Immune response to vaccination in patients with psoriasis treated with systemic therapies 82
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study 81
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 81
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 79
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study 78
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 78
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 77
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 77
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 77
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 76
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 75
Infectious adverse events in patients with atopic dermatitis treated with baricitinib 75
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 75
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 75
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 74
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 74
Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience 74
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 73
Alexithymia affects patients with hidradenitis suppurativa 73
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 72
Long-Term Real-World Safety Profile of Secukinumab Assessed Through a 9-Year Experience in Patients Affected by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Results From a Multicentric Retrospective Study 72
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 72
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement 72
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 71
Immunologic biomarkers for clinical and therapeutic management of psoriasis 71
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 70
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 70
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies 69
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 69
Optimizing acitretin use in patients with plaque psoriasis 69
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 69
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 67
Totale 9.604
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 0 20 1
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.859 45 374 116 272 85 252 121 90 39 93 147 225
2024/20252.959 60 40 286 66 283 129 92 93 492 251 597 570
2025/20267.352 1.291 202 591 941 1.042 331 1.480 413 452 541 68 0
Totale 14.761